AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular ...

They are generally classified according to the cancer's growth rate as high grade (fast growing ... of genetic subtypes in diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...

The following is a summary of “Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma,” published in the December 2024 issue of Hematology by ...

Lyell is focused on advancing next-generation CAR T cell therapies with the potential to deliver higher response rates and ...

RG-6540 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Primary Mediastinal B-Cell Lymphoma.

Learn about Nurix Therapeutics (NRIX) focusing on protein degradation in cancer treatment, with promising early-stage data ...